NRG
ALNY icon

Nemes Rush Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Nemes Rush Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.5K Hold
5
– – ﹤0.01% 820
2026
Q1 		$1.65K Hold
5
– – ﹤0.01% 772
2025
Q4 		$1.99K Buy
+5
New +$2.21K ﹤0.01% 734

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nemes Rush Group's ALNY Position: Q2 2026 in Review

Nemes Rush Group held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 5 shares worth $1.5K. The position accounts for ﹤0.01% of the portfolio, ranked #820.

Nemes Rush Group first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.99K in Q4 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Nemes Rush Group held 5 shares of Alnylam Pharmaceuticals worth $1.5K as of Q2 2026.
  • Nemes Rush Group left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Nemes Rush Group's portfolio in Q2 2026, its #820 holding.
  • Nemes Rush Group first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Nemes Rush Group's Alnylam Pharmaceuticals position peaked at $1.99K in Q4 2025.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.